This page shows what was measured, who it was measured in, and what that does not settle.
What Ixazomib Citrate does in the body
NINLARO ® is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
From the FDA-approved label: Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome. Ixazomib induced apoptosis of multiple myeloma cell lines in vitro. Ixazomib demonstrated in vitro cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines. In vivo, ixazomib demonstrated antitumor activity in a mouse multiple myeloma tumor xenograft model.
Why people take it. NINLARO ® is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 46CWK97Z3K · read 2026-08-29
Where each sentence above came from
The use the label states, quoted from it. No plain-language version of this sentence has been written.
The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.
No statement of the main limit is recorded.
The four opening statements run to 149 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Placebo
A placebo is a dummy treatment given so the real one can be compared with it.
A picture of it, and where the picture fails
A placebo is like a blank control in an experiment.
Where that stops being true. A blank does nothing. People given a placebo often do get better.
What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.
An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Randomisation 1: Number of participants with early treatment cessation
✗ The study did not show it
Who was studied
NCT03720041
How many people
740
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)
✗ The study did not show it
Who was studied
NCT01564537
How many people
722
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Progression Free Survival (PFS)
✗ The study did not show it
Who was studied
NCT02312258
How many people
706
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Progression Free Survival (PFS)
✗ The study did not show it
Who was studied
NCT01850524
How many people
705
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Progression Free Survival (PFS)
✗ The study did not show it
Who was studied
NCT02181413
How many people
656
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
the percentage of 2 year PFS(progression-free survival)
✗ The study did not show it
Who was studied
NCT05477797
How many people
420
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
NINLARO ® is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness of NINLARO have not been established in pediatric patients.”
US prescribing information · 038f2461-834b-4488-9ebd-863c83eef5a7 · read 2026-08-30
On older people, the label states: “Of the total number of subjects in clinical studies of NINLARO, 55% were 65 and over, while 17% were 75 and over.”
US prescribing information · 038f2461-834b-4488-9ebd-863c83eef5a7 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Based on its mechanism of action [see Clinical Pharmacology (12.1) ] and data from animal reproduction studies, NINLARO can cause fetal harm when administered to a pregnant woman.”
US prescribing information · 038f2461-834b-4488-9ebd-863c83eef5a7 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There are no data on the presence of ixazomib or its metabolites in human milk, the effects of the drug on the breast fed infant, or the effects of the drug on milk production.”
US prescribing information · 038f2461-834b-4488-9ebd-863c83eef5a7 · read 2026-08-30
On people with reduced liver function, the label states: “In patients with moderate or severe hepatic impairment, the mean AUC increased by 20% when compared to patients with normal hepatic function.”
US prescribing information · 038f2461-834b-4488-9ebd-863c83eef5a7 · read 2026-08-30
On people with reduced kidney function, the label states: “In patients with severe renal impairment or ESRD requiring dialysis, the mean AUC increased by 39% when compared to patients with normal renal function.”
US prescribing information · 038f2461-834b-4488-9ebd-863c83eef5a7 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S3, S4.
No source is stored against this line.
What is in the pack
Sold as capsule, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
7 products list this as an active ingredient in the United States drug directory. 7 of them contain it and nothing else.
FDA National Drug Code directory · 48957-0056 · read 2026-08-29
They are sold as capsule and powder, taken oral.
FDA National Drug Code directory · 48957-0056 · read 2026-08-29
The regulator's established pharmacologic class for it is proteasome inhibitor [epc] and proteasome inhibitors [moa].
FDA National Drug Code directory · 48957-0056 · read 2026-08-29
1 published label names it as an active ingredient. 1 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 038f2461-834b-4488-9ebd-863c83eef5a7 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 038f2461-834b-4488-9ebd-863c83eef5a7 · read 2026-08-29
NINLARO is oral at 3 DOSAGE FORMS AND STRENGTHS NINLARO is available in the following capsules: 4 mg ixazomib: Light orange gelatin capsule imprinted with "Takeda" on the cap and "4 mg" on the body in black ink. 3 mg ixazomib: Light grey…, recorded as fda label in effect 2026-08-11 in the United States.
US prescribing information · 038f2461-834b-4488-9ebd-863c83eef5a7 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Ixazomib Citrate studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Ixazomib Citrate are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
FDA substance identifier (UNII)
46CWK97Z3K
RxNorm concept
1723757
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Quoted from a stored source.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1, S3, S4.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
1 approved application covers products containing this substance. The earliest was NDA208462, approved 20151120 to TAKEDA PHARMS USA.
This order is fixed in code and does not count clicks or time on the page.
What is not here
9 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (11)
Q2
On the Ixazomib Citrate label: indicated for what?
"NINLARO ® is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma…": indications and usage on Ixazomib Citrate's label. DailyMed label · 038f2461-834b-4488-9ebd-863c83eef5a7 · 2026-08-11
Q3
140 registered trials of Ixazomib Citrate — at which phases?
Registered studies posting no result
61 of 140
140 registered studies of Ixazomib Citrate: 90 phase2, 61 phase1, 11 phase3, 5 phase4, 2 early phase1, 2 na or unstated. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"Sponsor's decision"; 33 of 140 registered studies
Show the evidence
Trial
NCT01659658
terminated; "Sponsor's decision"
NCT01887587
terminated; "SAE- risk of overall protocol treatment outweighs benefits"
NCT02030405
terminated; "Regulatory"
NCT02176486
terminated; "Insufficient enrollment, no safety or efficacy concerns"
NCT02302846
terminated; "Slow Accrual"
NCT02384746
terminated; "Low accrual"
14 further recorded trials
NCT02447887
terminated; "IRB study closure facilitated by Investigator"
NCT02516423
terminated; "DSMB recommendation due to slow accrual"
NCT02578121
withdrawn; "Investigator decided to close study without enrollment"
NCT02578511
withdrawn; "No enrollment, another competing study and difficult to find the right person to enroll on this study."
NCT02897830
terminated; "negatives results"
NCT02898259
terminated; "Funding was eliminated."
NCT02993094
terminated; "Due to slow recruitment, the study had to be terminated prematurely."
NCT03173092
terminated; "All participants on the study have concluded treatment, core study activities are complete, and the scientific goals of the study have been met."
NCT03422874
withdrawn; "Sponsor withdrew support"
NCT03457142
terminated; "funding ended"
NCT03492138
terminated; "Low enrollment"
NCT03506373
terminated; "Discontinued after interim analysis for futility; no treatment successes observed in the first 12 patients"
NCT03547700
terminated; "Lack of accrual"
NCT03590652
terminated; "The trial met its primary endpoint."
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Ixazomib Citrate used Ixazomib 2.5 mg — over how long?
studies of Ixazomib Citrate used the recorded amount. ClinicalTrials.gov · 2026-09-01
11 recorded entries; human; also "Ixazomib 2.5 mg", "Ixazomib 4 mg Capsule A", "Ixazomib 4 mg Capsule B"
Show the evidence
human
NCT01454076
Ixazomib 2.5 mg
NCT01454076
Ixazomib 4 mg Capsule A
NCT01454076
Ixazomib 4 mg Capsule B
NCT02250300
MLN9708 (2.3 mg)
NCT02250300
MLN9708 (4.0 mg)
NCT02250300
MLN9708 (3.0 mg)
5 more recorded rows
humanNCT02946047
Ixazomib 1 MG
humanNCT02946047
Ixazomib 2 MG
humanNCT02946047
Ixazomib 3 MG
humanNCT02946047
Ixazomib 4 MG
humanNCT03731832
Ixazomib 4.0 mg
recorded 2026-09-01 · last checked 2026-09-04
Q6
Ixazomib Citrate's half-life is 9.5 days — which schedules were studied?
9.5 days; The terminal half-life (t 1/2 ) of ixazomib was 9.5 days.
bioavailabilitypharmacokinetics
58 %; The mean absolute oral bioavailability was 58%, based on population PK analysis.
metabolismpharmacokinetics
Metabolism After oral administration of a radiolabeled dose, ixazomib represented 70% of total drug-related material in plasma.
recorded 2026-08-11 · last checked 2026-09-04
Q7
Which running trial of Ixazomib Citrate could settle lifespan?
NCT03618537 measures event free survival (EFS), reading out 2026-08.
4 open trials; n 17; "Ixazomib Maintenance Study in Patients With AL Amyloidosis"
Show the evidence
Trial
NCT03618537
"Ixazomib Maintenance Study in Patients With AL Amyloidosis"; n 17; "event free survival (EFS)"; 2026-08
NCT04009109
"Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM"; n 79; "Impact of Study Treatment on Progression Free Survival (PFS)"; 2027-06
NCT03763162
"Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma"; n 40; "Progression free survival (PFS)"; 2027-10-30
NCT05722405
"Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma"; n 100; "Progression-Free Survival (PFS)"; 2028-07-31
Q8
Which 18 trials of Ixazomib Citrate posted no result?
Posted no result
18 of 18 completed trials
Registrations
NCT02070458, NCT02406144, NCT02410694, NCT02228772, NCT02042989 and NCT01936532, and 12 more
Completion dates
oldest 2017-08-15; newest 2024-06-30
Show the evidence
Trial
NCT02070458
2017-08-15
NCT02406144
2017-11
NCT02410694
2019-05-02
NCT02228772
2019-11
NCT02042989
2020-01-22
NCT01936532
2020-06-04
12 further recorded trials
NCT02504359
2020-09-09
NCT02831686
2020-11-19
NCT02582359
2022-04
NCT03236792
2022-09-20
NCT02942095
2022-12-07
NCT02586038
2023-12
NCT03399539
2024-02-23
NCT04028115
2024-04-01
NCT03731832
2024-04-22
NCT02697383
2024-05-08
NCT02921893
2024-05-13
NCT04217967
2024-06-30
Q9
At the median, Ixazomib Citrate's trials enrolled 31.5 people — anything larger?
Median enrolment
31.5
Largest enrolment
774
Registered trials counted
140
Q10
What do 4682 spontaneous reports say about Ixazomib Citrate — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Ixazomib Citrate appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 4682 reaction mentions were counted: diarrhoea 997; plasma cell myeloma 811; nausea 660; pneumonia 586. FAERS via Open Targets · CHEMBL3545432 · 2026-06-24
Show the evidence
diarrhoea
997
plasma cell myeloma
811
nausea
660
pneumonia
586
neuropathy peripheral
437
thrombocytopenia
419
4 more recorded rows
platelet count decreased
335
constipation
236
neutrophil count decreased
128
cytopenia
73
recorded 2026-06-24 · last checked 2026-09-04
Q11
Which 10 reactions does Ixazomib Citrate's label not list?
Strong CYP3A inducers : Avoid concomitant use with NINLARO.
drug_interactions
( 7.1 , 12.3 ) 7.1 Strong CYP3A Inducers Avoid concomitant administration of NINLARO with strong CYP3A inducers (such as rifampin, phenytoin, carbamazepine, and St.
pharmacokinetics
At clinically relevant ixazomib concentrations, in vitro studies using human cDNA-expressed cytochrome P450 isozymes showed that no specific CYP isozyme predominantly contributes to ixazomib metabolism.
pharmacokinetics
Drug Interaction Studies Effect of Other Drugs on NINLARO Strong CYP3A Inducers Coadministration of NINLARO with rifampin decreased ixazomib C max by 54% and AUC by 74% [see Drug Interactions (7.1) ] .
pharmacokinetics
Strong CYP3A Inhibitors Coadministration of NINLARO with clarithromycin did not result in a clinically meaningful change in the systemic exposure of ixazomib.
pharmacokinetics
Strong CYP1A2 Inhibitors Coadministration of NINLARO with strong CYP1A2 inhibitors did not result in a clinically meaningful change in the systemic exposure of ixazomib based on a population PK analysis.
2 more recorded rows
Interaction statementpharmacokinetics
Ixazomib did not induce CYP1A2, CYP2B6, and CYP3A4/5 activity or corresponding immunoreactive protein levels.
Interaction statementpharmacokinetics
Transporter-Based Interactions Ixazomib is a low affinity substrate of P-gp.
ChEMBL 37 — CC BY-SA 3.0 Unported · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 6 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.